Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro

CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation

(2013) Erin J. Kaleta et al.   CLINICAL BIOCHEMISTRY

Ascites analysis by a microfluidic chip allows tumor-cell profiling

(2013) V. M. Peterson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer

(2013) Faruk Tas et al.   TUMOR BIOLOGY

EpCAM regulates cell cycle progression via control of cyclin D1 expression

(2012) A Chaves-Pérez et al.   ONCOGENE

Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage

(2011) Anne-Kathleen Rupp et al.   GYNECOLOGIC ONCOLOGY

EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis

(2011) Gilbert Spizzo et al.   JOURNAL OF CLINICAL PATHOLOGY

Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110

(2011) Silke Petsch et al.   mAbs

Hematologic and Oncologic Diseases and the Liver

(2010) Marvin M. Singh et al.   Clinics in Liver Disease

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Nuclear signalling by tumour-associated antigen EpCAM

(2009) Dorothea Maetzel et al.   NATURE CELL BIOLOGY

The stem cell niche of human livers: Symmetry between development and regeneration

(2008) Lili Zhang et al.   HEPATOLOGY